Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis.

The Lancet. Neurology·2026
Same author

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Neurology·2025
Same author

Depicting multiple sclerosis disease course using lesion parenchymal fraction: a quantified expression of the topographical model of multiple sclerosis.

Brain communications·2025
Same author

West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies.

Neurology. Clinical practice·2025
Same author

Spinal cord evaluation in multiple sclerosis: clinical and radiological associations, present and future.

Brain communications·2024

Related Experiment Video

Updated: Apr 8, 2026

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.5K

Alemtuzumab in multiple sclerosis: an update.

Robert H Gross1, Stephen Krieger1

  • 1Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Neurodegenerative Disease Management
|June 25, 2015
PubMed
Summary
This summary is machine-generated.

Alemtuzumab effectively treats active relapsing multiple sclerosis, outperforming interferon beta-1a. Close monitoring is essential due to potential side effects and its long-lasting immune effects.

Keywords:
active MSalemtuzumabdisease-modifying agentmonoclonal antibodymultiple sclerosis

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

4.0K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Related Experiment Videos

Last Updated: Apr 8, 2026

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

4.0K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Area of Science:

  • Neuroimmunology
  • Clinical Pharmacology

Background:

  • Disease-modifying therapies (DMTs) like interferon beta (IFN-β) reduce multiple sclerosis (MS) activity.
  • Some patients show incomplete response, intolerance, or contraindications to existing DMTs.

Purpose of the Study:

  • To evaluate alemtuzumab as a treatment option for active relapsing-remitting multiple sclerosis (RRMS).
  • To compare alemtuzumab's efficacy and safety against IFN-β-1a in RRMS patients.

Main Methods:

  • Two Phase III clinical trials assessed alemtuzumab in active RRMS.
  • Alemtuzumab, a lymphocyte-depleting monoclonal antibody, was administered intravenously.
  • Efficacy outcomes were compared with interferon beta-1a (IFN-β-1a) 44 mcg.

Main Results:

  • Alemtuzumab demonstrated superior clinical and radiographic efficacy compared to IFN-β-1a.
  • Key side effects included infusion reactions, infections, and secondary autoimmunity.
  • The treatment has a long-lasting biological effect requiring extended patient monitoring.

Conclusions:

  • Alemtuzumab represents a potent therapeutic choice for selected active RRMS patients.
  • Its efficacy is balanced by a significant side effect profile and the need for vigilant monitoring post-treatment.